Optical genome mapping refines genomic risk stratification in therapy-related myeloid neoplasms and younger myelodysplastic syndromes

Abstract excerpt

Accurate genomic characterization is essential for risk stratification in therapy-related myeloid neoplasms (t-MN) and younger myelodysplastic syndromes (yMDS), where chromosome banding analysis (CBA) has limited sensitivity. We analyzed 113 patients (48 t-MN, 65 yMDS) using optical genome mapping (OGM) integrated with CBA, targeted next-generation sequencing, and clinical data. OGM was interpretable in all cases...

Topics

Open a Topic to create a Post that cites this publication.

• Acute Myeloid Leukemia Research
• Cancer Genomics and Diagnostics
• Chromatin Remodeling and Cancer

Identifiers and source

Literature Corpus work

20a48640-d9e4-5c47-8f9d-3ed507f88fda

DOI

10.1038/s41698-026-01671-z